INNOVENT BIO (01801.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec29

Ping An Good Doctor Collaborates with Wuhan No.3 Hospital to Launch 'Direct Settlement' Service

19:11

Dec28

Innovent's DaBerXin® Approved for Neoadjuvant Therapy in Colorectal Cancer

23:40

Innovent Biologics Receives Approval for Pre-surgical Treatment Drugs for Colon Cancer

23:30

Dec25

Innovent's TABOSUN® Approved for Colorectal Cancer Treatment

08:45

Innosyne Biologics shareholders deposit stocks into HSBC

00:12

Dec23

Shanghai Market Supervision Administration Enforcement Team Signs Compliance System Construction Cooperation Memorandum with Innovent Biologics

05:48

Schedules & Filings

Schedules

Filings

Aug27

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 3.258 B, Net Income 456.59 M, EPS 0.2681

Mar26

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 2.909 B, Net Income 158.51 M, EPS 0.0951

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 2.123 B, Net Income -210.94 M, EPS -0.1299

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change